BETTER
HEALTH
BRIGHTER
FUTURES





PARTNERSHIP WITH THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA The Global Fund to Fight AIDS, Tuberculosis, and Malaria, established in 2002, is a cornerstone in the global fight against these three diseases. It also plays a vital role in strengthening health systems and enhancing pandemic preparedness. Its remarkable achievements highlight the power of international solidarity and innovative health financing.

The Global Fund's unwavering partnership with the European Commission (EC) has been instrumental to this success. The EC has played a pivotal role in shaping and supporting the Global Fund from its earliest days, contributing to the success of every single replenishment to date. Team Europe accounts for around one-third of the Global Fund's total funding – a testament to the EU's leadership in global health.

28.6% Total EU donors 71.4% Other donors

Key achievements since 2002:



Every \$1 invested by the Global Fund has leveraged \$3 in domestic health funding



Reduction of combined death rate from AIDS, TB, and malaria



65 million lives saved

As the Global Fund enters its 8th replenishment, we urge the Commission to harness the strength of this partnership to ensure better health for all and to pledge €715 million.

Why the Global Fund remains more relevant than ever

#### Strengthening health systems for resilient futures

The Global Fund is the world's largest multilateral provider of grants for strengthening health and community systems: it allocates \$2 billion annually to improve service delivery and reinforce workforce capacity, diagnostics, and supply chains. During the COVID-19 pandemic, the Global Fund delivered over \$4 billion in emergency support, complementing EU efforts to enhance outbreak preparedness and response.

Climate change represents a profound threat to the Global Fund's mission. Between 2023 and 2025, a significant portion of the Global Fund's investments - 71% - are going to the 50 most climate-vulnerable countries, demonstrating its commitment to building climate-resilient health systems. This dual focus on addressing immediate health needs and building long-term resilience exemplifies the Global Fund's comprehensive approach.

The Global Fund is our collective defense mechanism: the laboratories, disease surveillance systems, community networks, supply chains, and other health system components built to fight HIV, TB and malaria, and strengthened in response to COVID-19, provide a platform to protect communities around the world from mpox and other disease outbreaks.

## Ending HIV, TB and Malaria & addressing health inequities

The Global Fund's impact is felt most profoundly in the lives it saves and the systemic inequities it addresses. Its investments have led to a 61% reduction in mortality rates from HIV, TB, and malaria in the countries it supports. By tackling structural barriers such as gender inequality and human rights challenges, the Global Fund ensures that everyone has access to essential health services.

HIV rates among adolescent girls and young women in 13 priority countries have dropped by 69% since 2010.

### Persevering in the face of conflict:

The Global Fund provides life-saving healthcare in conflict zones by leveraging flexible financing and rapidly adapting programs to challenging environments. In Ukraine, where war has devastated healthcare infrastructure, the Global Fund supports mobile health clinics delivering HIV and TB services to hard-to-reach frontline areas. Since 2022, and in less than three years, the Global Fund's support has helped establish a new healthcare delivery ecosystem, ensuring vital services for conflict-affected populations where medical infrastructure has been destroyed. By partnering with local stakeholders, the Global Fund strengthens health systems to ensure care reaches the most vulnerable communities.

### Leveraging innovation and partnerships:

The Global Fund's success is underpinned by its unique model of partnership. By forging strong alliances with governments, civil society, technical agencies, and the private sector, the Global Fund fosters collaboration and leverages innovation to effectively combat HIV, tuberculosis, and malaria:

- Its collaboration with European companies such as
  Orange, Siemens Healthineers, and Delft Imaging
   has yielded groundbreaking solutions, including
  Al-enhanced diagnostics for tuberculosis, while also
  positioning European expertise and innovation at the
  forefront of global health advancements.
- The Global Fund works closely with other global health institutions, including the WHO, Unitaid, and Gavi, the Vaccine Alliance. By streamlining procurement, accelerating the development and roll-out of lifesaving tools and strengthening health systems, these collaborations maximize the Global Fund's ability to drive sustainable health outcomes.

#### Building economic prosperity

The economic benefits of the Global Fund's work are significant. For instance, market-shaping initiatives have dramatically reduced the cost of life-saving treatments, with the price of antiretroviral therapy for HIV falling from \$10,000 per person annually in 2002 to less than \$40 today.

Its health investments have transformative power. Between 2002-2023, in the countries where the Global Fund invests, its programs have generated:





\$85 Billion
Cost savings to the health system

Malaria exemplifies the strong return on investment in fighting infectious diseases. Reducing malaria by **90**% by 2030 could:




boost to the economies of malaria-endemic countries



\$3.9 Billion boost in exports that would directly benefit G7 countries

# How the Global Fund contributes to EU Priorities



Our call to action: the EC must pledge €715 million to the Global Fund

The Global Fund and the EU share a commitment to ending HIV, tuberculosis, and malaria by 2030. However, this path is fraught with challenges, including climate change, conflicts, and persistent health inequities. Continued investment in the Global Fund is essential to overcoming these obstacles.

For its 8th replenishment, the Global Fund seeks to raise US\$18 billion, which will allow it to save an estimated 23 million additional lives. The economic benefits further underscore the value of these investments: every dollar invested in fighting HIV, tuberculosis, and malaria generates US\$19 in health gains and economic returns, benefiting entire societies.

This is why we urge the EC to pledge at least €715 million to the Global Fund's eighth replenishment. This financial commitment will build upon the EU's legacy of global health leadership. It will not only save lives but also strengthen health systems, enhance global health security, and drive progress toward a healthier and more equitable world.

February 2025

